The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration

Vet J. 2016 Feb:208:90-2. doi: 10.1016/j.tvjl.2015.10.012. Epub 2015 Oct 13.

Abstract

Tulobuterol is a β2-adrenergic agonist that was the first bronchodilator approved as a transdermal patch for humans. Previous studies have examined the pharmacokinetics of tulobuterol in humans but not in the veterinary species. In this study, the pharmacokinetics of tulobuterol was examined in healthy Beagle dogs after transdermal and intravenous administration. The Cmax was 2.09 ng/mL at 16.0 h for a 0.2 mg/kg patch and 4.85 ng/mL at 13.6 h for a 0.4 mg/kg patch. The effective blood level in humans is 1-3 ng/mL, a concentration achieved using the 0.2 mg/kg patch in dogs. In conclusion, application of a 0.2 mg/kg tulobuterol patch to healthy dogs led to an apparently effective blood concentration for 24 h.

Keywords: Canine; Pharmacokinetics; Transdermal patch; Tulobuterol; β(2)-adrenoceptor agonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Administration, Intravenous / veterinary
  • Adrenergic beta-2 Receptor Agonists / blood
  • Adrenergic beta-2 Receptor Agonists / pharmacokinetics*
  • Animals
  • Bronchodilator Agents / blood
  • Bronchodilator Agents / pharmacokinetics*
  • Dogs / metabolism*
  • Random Allocation
  • Terbutaline / analogs & derivatives*
  • Terbutaline / blood
  • Terbutaline / pharmacokinetics

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • tulobuterol
  • Terbutaline